NASDAQ:REGN

Regeneron Pharmaceuticals (REGN) Stock Forecast, Price & News

$822.96

-11.61 (-1.39%)

(As of 09/29/2023 ET)

Compare

Today's Range: $819.91
▼
$833.68
50-Day Range: $727.13
▼
$844.37
52-Week Range: $668.00
▼
$847.50

Volume: 409,771 shs
Average Volume: 383,792 shs
Market Capitalization: $89.34 billion

P/E Ratio: 21.75
Dividend Yield: N/A
Price Target: $900.92

Regeneron Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.70 Rating Score
Upside/Downside: 9.5% Upside
$900.92 Price Target
Short Interest: Healthy
1.40% of Float Sold Short
Dividend Strength: N/A
Sustainability: -2.69
Upright™ Environmental Score
News Sentiment: 1.08
Based on 23 Articles This Week
Insider Trading: Selling Shares
$27.23 M Sold Last Quarter
Proj. Earnings Growth: 2.60%
From $35.42 to $36.34 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.24 out of 5 stars

Medical Sector

376th out of 972 stocks

Pharmaceutical Preparations Industry

161st out of 455 stocks

2.4

Analyst's Opinion

Consensus Rating
Regeneron Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 20 buy ratings, 6 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $900.92, Regeneron Pharmaceuticals has a forecasted upside of 9.5% from its current price of $822.96.
Amount of Analyst Coverage
Regeneron Pharmaceuticals has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

4.0

Short Interest

Percentage of Shares Shorted
1.40% of the float of Regeneron Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Regeneron Pharmaceuticals has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Regeneron Pharmaceuticals has recently decreased by 2.03%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Regeneron Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Regeneron Pharmaceuticals does not have a long track record of dividend growth.

2.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Regeneron Pharmaceuticals has received a 8.96% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Aflibercept", "Casirivimab and imdevimab", and "Alirocumab" products. See details.
Environmental Sustainability
The Environmental Impact score for Regeneron Pharmaceuticals is -2.69.

2.8

News and Social Media Coverage

News Sentiment
Regeneron Pharmaceuticals has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 23 news articles for Regeneron Pharmaceuticals this week, compared to 11 articles on an average week.
Search Interest
Only 4 people have searched for REGN on MarketBeat in the last 30 days. This is a decrease of -79% compared to the previous 30 days.
MarketBeat Follows
Only 14 people have added Regeneron Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -7% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Regeneron Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $27,232,176.00 in company stock.
Percentage Held by Insiders
Only 8.83% of the stock of Regeneron Pharmaceuticals is held by insiders.
Percentage Held by Institutions
84.15% of the stock of Regeneron Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Regeneron Pharmaceuticals are expected to grow by 2.60% in the coming year, from $35.42 to $36.34 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Regeneron Pharmaceuticals is 21.75, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 105.12.
Price to Earnings Ratio vs. Sector
The P/E ratio of Regeneron Pharmaceuticals is 21.75, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 73.01.
Price to Earnings Growth Ratio
Regeneron Pharmaceuticals has a PEG Ratio of 2.45. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Regeneron Pharmaceuticals has a P/B Ratio of 3.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Regeneron Pharmaceuticals (NASDAQ:REGN) Stock

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

REGN Price History

30 days | 90 days | 365 days | Advanced Chart

REGN Stock News Headlines

September 25, 2023 | marketbeat.com

Are Gene Therapy Stocks The Market's Next Big Winners? (REGN)

Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.

September 25, 2023 | marketbeat.com

Argenx's 28% Surge & Promising Product Propel Investor Confidence (REGN)

Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.

October 1, 2023 | Legacy Research (Ad)

Elon Did It Again: This Could be Bigger than Tesla

Love him or hate him, it’s hard to deny Elon Musk is a genius. After revolutionizing online payment processing (PayPal), space exploration (SpaceX), and the auto industry (Tesla)... He’s getting ready to do it again with his new AI venture.

October 1, 2023 | americanbankingnews.com

Regeneron Pharmaceuticals (NASDAQ:REGN) PT Raised to $680.00 at Bank of America

September 30, 2023 | finance.yahoo.com

Stock Split Watch: Is Regeneron Pharmaceuticals Next?

September 29, 2023 | markets.businessinsider.com

Regeneron Pharma Reports FDA Priority Review For Odronextamab BLA - Quick Facts

September 29, 2023 | finance.yahoo.com

Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) Accepted for FDA Priority Review

September 28, 2023 | finance.yahoo.com

Regeneron to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on November 2, 2023

October 1, 2023 | Goldco (Ad)

Ben Stein FREE Report: How Americans Are RUINING Retirement

There’s a new report just out from famed author, actor and economist Ben Stein. In this FREE REPORT, Ben reveals the lessons he learned from his late father and economist Herbert Stein. Discover how everyday Americans are currently ruining their retirements, and how YOU can save yours!

September 27, 2023 | finance.yahoo.com

Regeneron Pharmaceuticals Stock Earns 85 RS Rating

September 26, 2023 | finance.yahoo.com

Dow Jones Futures Rise After Market Correction Worsens; Meta AI News Due

September 26, 2023 | finance.yahoo.com

Dupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review

September 26, 2023 | americanbankingnews.com

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Consensus Recommendation of "Moderate Buy" from Analysts

September 25, 2023 | finance.yahoo.com

Ultragenyx Launches Evkeeza® (evinacumab for injection) in Canada for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)

September 25, 2023 | msn.com

Regeneron finalizes acquisition of Decibel Therapeutics, enhancing gene therapy portfolio

September 23, 2023 | finance.yahoo.com

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Could Be 40% Below Their Intrinsic Value Estimate

September 23, 2023 | americanbankingnews.com

Regeneron Pharmaceuticals (NASDAQ:REGN) Earns Neutral Rating from Cantor Fitzgerald

September 22, 2023 | finance.yahoo.com

Top Stock Reports for Amazon.com, Boeing, Regeneron & Others

September 21, 2023 | markets.businessinsider.com

Analyst Expectations for Regeneron Pharmaceuticals's Future

September 20, 2023 | msn.com

Regeneron’s Eylea HD Gets FDA Approval, Boosting Company’s Growth Outlook

September 20, 2023 | finance.yahoo.com

This Recent FDA Approval Could Give Regeneron's Top Line a Big Boost

September 19, 2023 | seekingalpha.com

Regeneron Pharmaceuticals: Game-Changing Discoveries In Healthcare

September 15, 2023 | msn.com

Argus Research Maintains Regeneron Pharmaceuticals (REGN) Buy Recommendation

September 15, 2023 | msn.com

WestPark Capital Initiates Coverage of Regeneron Pharmaceuticals (REGN) with Hold Recommendation

September 11, 2023 | seekingalpha.com

Regeneron Pharmaceuticals, Inc. (REGN) Management presents at Morgan Stanley 21st Annual Global Healthcare Conference (Transcript)

September 11, 2023 | seekingalpha.com

Regeneron Pharmaceuticals, Inc. (REGN) Morgan Stanley 21st Annual Global Healthcare Conference (Transcript)

September 11, 2023 | forbes.com

Is Regeneron Stock Fully Valued At $820?

See More Headlines

Receive REGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

REGN Company Calendar

Last Earnings: 8/03/2023
Today: 10/01/2023
Next Earnings (Confirmed): 11/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:REGN
CUSIP: 75886F10
CIK: 872589
Web: www.regeneron.com
Phone: (914) 847-7000
Fax: 914-347-2113
Employees: 11,851
Year Founded: 1988

Price Target and Rating

Average Stock Price Forecast: $900.92
High Stock Price Forecast: $1,050.00
Low Stock Price Forecast: $680.00
Forecasted Upside/Downside: +9.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.70
Research Coverage: 27 Analysts

Profitability

EPS (Most Recent Fiscal Year): $37.83
Trailing P/E Ratio: 21.75
Forward P/E Ratio: 23.23
P/E Growth: 2.48
Net Income: $4.34 billion
Net Margins: 33.93%
Pretax Margin: 37.69%
Return on Equity: 19.19%
Return on Assets: 14.94%

Debt

Debt-to-Equity Ratio: 0.11
Current Ratio: 5.45
Quick Ratio: 4.64

Sales & Book Value

Annual Sales: $12.17 billion
Price / Sales: 7.34
Cash Flow: $43.91 per share
Price / Cash Flow: 18.74
Book Value: $207.31 per share
Price / Book: 3.97

Miscellaneous

Outstanding Shares: 108,560,000
Free Float: 98,973,000
Market Cap: $89.34 billion
Optionable: Optionable
Beta: 0.19

Social Links

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Dr. Leonard S. Schleifer M.D. (Age 70)
Ph.D., Co-Founder, Pres, CEO & Co-Chairman
Comp: $7M

Dr. George D. Yancopoulos M.D. (Age 63)
Ph.D., Co-Founder, Pres, Chief Scientific Officer & Co-Chairman
Comp: $6.59M

Mr. Robert E. Landry Jr. (Age 59)
Exec. VP of Fin. & CFO
Comp: $1.84M

Dr. Andrew J. Murphy Ph.D. (Age 64)
Exec. VP of Research
Comp: $1.62M

Mr. Daniel P. Van Plew (Age 50)
Exec. VP and GM of Industrial Operations & Product Supply
Comp: $1.95M

Ms. Marion E. McCourt (Age 63)
Exec. VP of Commercial
Comp: $1.5M

Ms. Patrice Gilooly
Sr. VP of Quality Assurance & Operations

Mr. Christopher R. Fenimore CPA (Age 52)
Sr. VP, Head of Accounting & Controller

Mr. Gerald Underwood
Sr. VP of Technical Operations

Mr. Bob McCowan
Sr. VP of IT & Chief Information Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

REGN Stock - Frequently Asked Questions

Should I buy or sell Regeneron Pharmaceuticals stock right now?: 27 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 6 hold ratings and 20 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" REGN shares.
View REGN analyst ratings or view top-rated stocks.
What is Regeneron Pharmaceuticals' stock price forecast for 2023?: 27 brokerages have issued 12-month target prices for Regeneron Pharmaceuticals' stock. Their REGN share price forecasts range from $680.00 to $1,050.00. On average, they expect the company's stock price to reach $900.92 in the next twelve months. This suggests a possible upside of 9.5% from the stock's current price.
View analysts price targets for REGN or view top-rated stocks among Wall Street analysts.
How have REGN shares performed in 2023?: Regeneron Pharmaceuticals' stock was trading at $721.49 on January 1st, 2023. Since then, REGN shares have increased by 14.1% and is now trading at $822.96.
View the best growth stocks for 2023 here.
When is Regeneron Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our REGN earnings forecast.
How can I listen to Regeneron Pharmaceuticals' earnings call?: Regeneron Pharmaceuticals will be holding an earnings conference call on Thursday, November 2nd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.
How were Regeneron Pharmaceuticals' earnings last quarter?: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) posted its earnings results on Thursday, August, 3rd. The biopharmaceutical company reported $10.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.48 by $1.76. The biopharmaceutical company earned $3.16 billion during the quarter, compared to analyst estimates of $3.02 billion. Regeneron Pharmaceuticals had a trailing twelve-month return on equity of 19.19% and a net margin of 33.93%. Regeneron Pharmaceuticals's quarterly revenue was up 10.5% compared to the same quarter last year. During the same period last year, the company earned $9.77 EPS.
Read the conference call transcript.
What ETFs hold Regeneron Pharmaceuticals' stock?: ETFs with the largest weight of Regeneron Pharmaceuticals (NASDAQ:REGN) stock in their portfolio include Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB), VanEck Biotech ETF (BBH), ProShares Ultra Nasdaq Biotechnology (BIB), Invesco Biotechnology & Genome ETF (PBE), iShares Genomics Immunology and Healthcare ETF (IDNA), Subversive Mental Health ETF (SANE) and 2ndVote Life Neutral Plus ETF (LYFE).
What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO?: 423 employees have rated Regeneron Pharmaceuticals Chief Executive Officer Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among the company's employees.

What other stocks do shareholders of Regeneron Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and Salesforce (CRM).
What is Regeneron Pharmaceuticals' stock symbol?: Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."
How do I buy shares of Regeneron Pharmaceuticals?: Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Regeneron Pharmaceuticals' stock price today?: One share of REGN stock can currently be purchased for approximately $822.96.
How much money does Regeneron Pharmaceuticals make?: Regeneron Pharmaceuticals (NASDAQ:REGN) has a market capitalization of $89.34 billion and generates $12.17 billion in revenue each year. The biopharmaceutical company earns $4.34 billion in net income (profit) each year or $37.83 on an earnings per share basis.
How many employees does Regeneron Pharmaceuticals have?: The company employs 11,851 workers across the globe.
Does Regeneron Pharmaceuticals have any subsidiaries?: The following companies are subsidiares of Regeneron Pharmaceuticals: Eastside Campus Holdings LLC, Loop Road Holdings LLC, OSMR Holdings, Old Saw Mill Holdings LLC, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, Regeneron Canada Company, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron GmbH, Regeneron Healthcare Solutions Inc., Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron NL B.V., Regeneron Spain S.L.U., Regeneron UK Limited, and Rockwood Road Holdings LLC.
Read More
How can I contact Regeneron Pharmaceuticals?: Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The official website for the company is www.regeneron.com. The biopharmaceutical company can be reached via phone at (914) 847-7000, via email at invest@regeneron.com, or via fax at 914-347-2113.

This page (NASDAQ:REGN) was last updated on 10/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial